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The swift development of SARS-CoV-2 vaccines has been met with world-
wide commendation. However, in the context of an ongoing pandemic
there is an interplay between infection and vaccination. While infection
can grow exponentially, vaccination rates are generally limited by supply
and logistics. With the first SARS-CoV-2 vaccines receiving medical
approval requiring two doses, there has been scrutiny on the spacing
between doses; an elongated period between doses allows more of the popu-
lation to receive a first vaccine dose in the short-term generating wide-spread
partial immunity. Focusing on data from England, we investigated prioriti-
zation of a one dose or two dose vaccination schedule given a fixed number
of vaccine doses and with respect to a measure of maximizing averted
deaths. We optimized outcomes for two different estimates of population
size and relative risk of mortality for at-risk groups within the Phase 1 vac-
cine priority order. Vaccines offering relatively high protection from the first
dose favour strategies that prioritize giving more people one dose, although
with increasing vaccine supply eventually those eligible and accepting vac-
cination will receive two doses. While optimal dose timing can substantially
reduce the overall mortality risk, there needs to be careful consideration of
the logistics of vaccine delivery.1. Introduction
Vaccination has been seen as a key tool in the fight against SARS-CoV-2,
although deployment provides multiple unique challenges that are not encoun-
tered by other vaccination programmes. In short, there is a race between
infection and vaccination, with vaccination rates currently limited by supply
and logistics, whereas infection can grow exponentially.
The vaccines developed represent a major technological achievement and
have been shown to generate significant immune responses, as well as offering
considerable protection against disease [1–5]. Field data from Israel and the UK
suggested that protection against severe disease (hospitalization or death) may
be even greater [6,7].
The data and science surrounding the SARS-Cov-2 virus are fast moving, so
much so that publications can rarely keep pace. This paper was originally written
in January 2021 to address contemporary public health questions. As such, this
paper is largely a record of the state of our modelling at that time, although
we interpret the results in terms of recent data and policy questions.
At the original time of writing, in the UK the two vaccines deployed as part
of the vaccination programme were the Pfizer/BioNTech and Oxford/AstraZe-
neca vaccines. The mRNA Pfizer/BioNTech vaccine was approved by the
Medicines and Healthcare products Regulatory Agency (MHRA) on 2 Decem-









































vectored vaccine, has been the main component of the UK
vaccination programme since it received approval for use
by the MHRA on 30 December 2020 [9]. Both require two
doses to be administered to maximize efficacy and longevity
of immunity (with the duration of vaccine-derived immunity
still uncertain).
A key question, given the urgency to achieve high levels
of protection in the population, is the appropriate interval
between first and second doses—often conceptualized as
prioritization of first or second doses. A longer interval
allows more people to be given partial protection from one
dose over relatively short time scales, whereas a shorter inter-
val will provide greater (although not complete) protection to
the most vulnerable. In deciding between these two options,
a number of factors need to be considered: the relatively high
efficacy of the first dose from 3 to 12 weeks after vaccination
[10]; the high levels of SARS-CoV-2 prevalence [11], COVID-
19 morbidity [12] and COVID-19 mortality [13] since the start
of the vaccine programme; the evidence that the Oxford/
AstraZeneca vaccine provides greater second dose efficacy
with a spacing of 12 weeks or more [5]; and the initial lack
of Phase 3 trial data on single dose vaccine performance
beyond three weeks for the Pfizer/BioNTech vaccine [1].
On short-term timescales, and in the absence of risk-struc-
ture or the potential for differential rates of waning immunity,
if the efficacy from one dose is more than half the efficacy
from two doses, then it is always preferable to prioritize vac-
cinating as many people as possible with one dose. Yet, given
clear variation in the burden of severe outcomes caused by
COVID-19, the prioritization of dosing schedules merits
quantitative evaluation; such analyses have been performed
in a non-UK context [14–16].
In this paper, we study prioritization of a one dose or two
dose vaccination schedule given a fixed number of vaccine
doses and with respect to a measure of maximizing averted
deaths. We performed this analysis in the context of the
population of England and age-stratified risk mortality. We
recognize that, while averted deaths are one important indi-
cator to inform the SARS-CoV-2 vaccination programme, in
reality there are multiple relevant indicators for vaccination
as a major public health intervention (for example, averted
hospital admissions, averted long-COVID cases and averted
quality adjusted life years lost). We stress that the analysis
we present can be readily applied to other contexts and
refined using alternative assumptions and outcome criteria.
Using a simple algorithmic method, we sought generic
insights into the benefits of prioritizing either first or
second vaccine doses according to two types of strategy for
vaccine dose allocation: (i) giving as many people one dose
or as many people two doses as permitted by the number
of doses available (homogeneous strategy); (ii) adding flexi-
bility to the allocation scheme by allowing for a given
percentage of vaccine doses being used for first doses, with
the remainder used for second doses (heterogeneous strat-
egy). Throughout, we explored the sensitivity to the relative
efficacy of the first vaccine dose (compared to the efficacy
attained following two vaccine doses). We acknowledge
that this is a simplified representation of a complex dynamic
process, whereby new supplies of vaccine are being manufac-
tured and distributed over time, where second dose efficacy
may change depending on the inter-dose separation [5,17]
and where there can be an intrinsic feedback between vacci-
nation and population-level incidence. Nevertheless,parsimonious model structures (such as the one used in this
study) may be swiftly developed and applied, whereas
models with additional complexities typically require
longer development times, finer-resolution data to be reliably
parameterized and can result in parameter inference becom-
ing more computationally intensive [18]. Timely delivery of
findings before a policy decision is taken can be worth
more than using a more complex method and obtaining
results afterwards, provided any methodological limitations
are made clear [19]. In the discussion, we expand on how
the findings from these theoretical results need to be inter-
preted to apply to the situation facing England, the UK and
other nations.2. Methods
2.1. Data on age-dependent mortality risk
We base our analysis on the estimated age distribution of mortality
due to COVID-19 in the UK, with a particular focus on the Joint
Committee on Vaccination and Immunization (JCVI) Phase 1 pri-
ority groups for vaccination [20]. The nine target groups within
the first phase of the vaccination programme encompass care
home residents and workers, healthcare workers, all those clini-
cally extremely vulnerable (CEV) and with underlying health
conditions (UHC), and all those aged 50 years and above.
Due to the absence of precise estimates for either the size of
each priority group or the relative risk of COVID-19 mortality
for individuals in each group (compared to the overall population
average), we considered two different sets of assumptions around
these two statistics (labelled ‘Age only’ and ‘Priority Group esti-
mate’), with details of the two estimates provided in table 1.
For the age-only model, estimation of risk was based solely
on the age-distribution of mortality due to COVID-19 in England
(using deaths within 28 days of a confirmed SARS-CoV-2 posi-
tive test, data from Public Health England (PHE)), during the
period 1 September 2020 until 1 February 2021, compared with
the underlying population pyramid for England using mid-
2019 Office for National Statistics (ONS) population estimates
(figure 1) [21]. It is evident that older age groups suffered the
greatest mortality, with 60% of deaths due to COVID-19 in
those over 80 years of age even though they only comprise 5%
of the population.
For the Priority Group estimate, we amended the groups
described for the age-only estimate to include the JCVI Phase 1
priority groups, assuming that this did not change the relative
mortality risk of the age groups (under 80 years old) previously
calculated. Note that the Priority Group estimate including care
home residents and staff, healthcare workers, the clinically extre-
mely vulnerable and those with underlying health conditions
meant the total number of individuals differed between the Pri-
ority Group estimate and the age-only estimate. The relative risk
of care home residents and staff is based upon approximately 14
thousand care home deaths in the period since 7 August 2020 to
the beginning of February 2021 [22], with the risk in the over-80s
scaled to account for the greater risk of death within care homes.
We assumed risks for those clinically extremely vulnerable to be
equal to those aged 70–74, which also occupy priority group
4. We assumed risks for those with underlying health conditions
(group 6) to lie equidistant between groups 5 and 7. Population
estimates for these priority groups were provided by the
Department of Health and Social Care (DHSC) [23].
2.2. Vaccine assumptions
Using the population size data (Pp) for each priority group, the
associated relative risk of COVID-19 mortality (RRp) and
Table 1. Estimates of priority group population size and relative mortality risk. The age-only estimates were based on age-group data (mid-2019 estimates) for
England [21] and the age distribution of mortality due to COVID-19 in the UK during the period 1 September 2020 until 1 February 2021 (data provided by
Public Health England 2021, personal communication). We based the Priority Group estimate on age-structured mortality data in the second wave using priority
group population estimates from DHSC [22]. As the Priority Group estimate included care home residents and staff, healthcare workers (HCW), the clinically
extremely vulnerable (CEV) and those with underlying health conditions (UHC), the total number of individuals differed between the Priority Group estimate and
the age-only estimate. Note that the group 2 category ‘≥80 years & HCW’ for the age group only estimate corresponded to just those aged 80 years and
above, whereas for the Priority Group estimate ‘≥80 years & HCW’ included healthcare workers and those aged 80 years or above. Similarly, for the group 4
category ‘70–74 years & CEV’, the age groups only estimate included only those aged 70–74 years, while for the Priority Group estimate ‘70–74 years & CEV’
included both those aged 70–74 years old and the clinically extremely vulnerable. We measured the relative risk of COVID-19 mortality for individuals in each
group relative to the overall population averaged mortality risk. We give population sizes to one decimal place and relative risk values to either one decimal
place or two significant figures (dependent on which format provided greater precision).
age groups only priority group estimate
priority group, p size, Pp (millions) relative risk, RRp size, Pp (millions) relative risk, RRp
1. care homes — — 0.7 17.0
2. ≥80 years & HCW 2.8 12.3 6.0 6.8
3. 75–79 years 1.9 3.9 1.9 3.9
4. 70–74 years & CEV 2.7 2.0 3.7 2.0
5. 65–69 years 2.8 1.2 2.4 1.2
6. UHC — — 6.2 1.0
7. 60–64 years 3.0 0.77 1.5 0.77
8. 55–59 years 3.6 0.43 2.0 0.43
9. 50–54 years 3.9 0.25 2.3 0.25









































estimates of vaccine efficacy following one or two doses (VE1
and VE2), we calculated the deaths averted given an assumed








ðv1pVER þ v2pÞPpRRp, ð2:2Þ
where v1p and v
2
p are the proportions of each priority group p that
receive just one dose or two doses of the vaccine respectively. To
further reduce the degrees of freedom of this calculation, it is suf-
ficient to know the ratio of the vaccine efficacy from the first dose
compared to the second VER =VE1/VE2, which we term relative
efficacy of the first dose.
2.2.1. Vaccine efficacy
At the original time of writing (in January 2021) the data on
vaccine effectiveness in averting deaths due to SARS-CoV-2
infection following first and second dose with the vaccine were
limited. We used the central estimates of vaccine efficacy against
disease reported from clinical trial data to guide our range of
relative efficacy: Pfizer/BioNTech (89% from first dose; 95%
from two doses) [1]; Oxford/AstraZeneca (76% from first dose;
81% from two doses) [5]. This would imply that the relative effi-
cacy of the first dose (VER) is in the region of 93% for the Pfizer
vaccine and the Oxford/AstraZeneca vaccine. In addition, there
were data reported from the UK on mortality in those over 80
years old suggesting that the first dose of Pfizer vaccine reduced
deaths by around 80%, which acted as a lower bound for the rela-
tive efficacy of the first dose against mortality [7].
These early data have now been superseded by more detailed
analysis of the efficacy of the vaccines in the general population.
For England, data on vaccine efficacy are calculated by PHE.Recent estimates of vaccine efficacy against COVID-19 mortality,
as of July 2021, are 70–80% and 95–99% for one dose and two
doses of the Pfizer/BioNTech vaccine, and 75–85% and 75–99%
for one dose and two doses of the Oxford/AstraZeneca vaccine
[24]. Taking the upper and lower bound of each range, this
would give a relative efficacy of the first dose (VER) of between
71% and 84% for the Pfizer vaccine, while for the AstraZeneca
vaccine the estimate is between 76% and over 100% due to the
greater uncertainty in the data. These estimates of efficacy against
mortality due to COVID-19 have been generated for the Alpha
(B.1.1.7) variant. For the Delta (B.1.617.2) variant, information
on vaccine efficacy against mortality is still not available, but pre-
liminary evidence suggests that the relative efficacy of the first
dose may be lower.2.2.2. Strategies for vaccine dose allocation
We examined two types of strategy for dose allocation, which we
describe as: (i) homogeneous strategy and (ii) heterogeneous
strategy.
Homogeneous strategy
For a given number of available doses (V) and for a given relative
efficacy from the first dose compared to the second (VER), we
first examined the question of whether to completely prioritize
one dose or two doses of the vaccine. This essentially is a ques-
tion of whether there is a greater number of expected deaths
averted from giving as many people as possible one dose or
two doses.
We compared the relative risks in the different age groups
(table 1) and computed the relative number of deaths averted
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Figure 1. Graphical representation of the data in table 1 showing the estimated population size (red) and the relative risk of mortality from COVID-19 (blue). (a) The















































where there is a strict limit on the number of available doses:P
p v
1




pPp ¼ V. We note that this is a relative
measure as predicting the scale of the future cases, hospitaliz-
ation and deaths is contingent on a number of policy decisions.
In all scenarios, we assumed 90% vaccine uptake (v1p  0:9 or
v2p  0:9), independent of age and priority group.
Given that the relative risk of COVID-19 mortality (RRp)
decreases monotonically between risk groups, it is clear that
the optimal deployment of either one of two doses must
similarly decline monotonically (0:9  v11  v12 . . .  v19 and
similarly for the second dose 0:9  v21  v22 . . .  v29). Moreover,
it is always better to maximally vaccinate the higher-risk
groups before preceding to lower-risk ones; therefore, solutions
are generally of the form: ðv11, . . . , v1q1, v1q , v1qþ1, . . . , v19Þ ¼
ð0:9, . . . , 0:9, v1q , 0, . . . , 0Þ which corresponds to completely vac-
cinating groups 1 to q− 1, partially vaccinating group q, and not
yet vaccinating the remaining lower-risk groups. This enables us
to calculate the optimal deployment of vaccine across all priority
groups without having to perform an exhaustive combinatorial
search.
Heterogeneous strategy
We extended our initial analysis to consider a heterogeneous
strategy. For a given number of doses, we sought the optimal
deployment of a mixed scheme where some priority groups
can be targeted for two doses while others receive one.
As an example, based on English population data, supposing
we had 6.6 million doses of vaccine, these could either give all
those aged 80 and above two doses, or it could give everyone
aged 75 and above, and some of those in the 70–74 years age
group, one dose. Again, our aim is to maximize the number of









ðv1p þ 2v2pÞPp ¼ V:Again, due to the monotonicity on the relative risk of mortality,
we can insist on a simple ordering of vaccination (0:9  v11 
v12 . . .  v19 and 0:9  v21  v22 . . .  v29); and again, we expect to
maximally vaccinate higher risk groups before moving to lower
ones. This essentially means we search over the number of
vaccines allocated to second rather than first doses.
We studied the optimal allocation of vaccine for the two esti-
mates of priority group size and relative risk (either based on
age-structure only or using Priority Group estimates), and for a
range of relative efficacy of one dose compared to two doses.
We assumed vaccine uptake of 90% (to set the scale of vacci-
nation in each priority group) and ignored the impact of
transmission blocking (which is difficult to incorporate in this
static model and is still not well quantified).
All computations and visualizations were performed in
MATLAB.3. Results
3.1. Homogeneous strategy
For a given number of vaccine doses (V) and considering vac-
cine targeting towards age-group based priority groups, we
considered when it is optimal to focus all vaccine resources
on maximizing the number of people receiving one dose or
concentrate on ensuring that the most vulnerable groups
get two doses.
When the number of vaccines available is insufficient to
cover a specified age range or priority group, there is a
choice between giving one dose to some proportion of the
target group or two doses to only half that number. In this situ-
ation, and ignoring the implications of generating long-term
immunity, a one dose strategy would be favoured if 2VE1 >
VE2 (VER > 0.5). For a larger available number of vaccine
doses, we are faced with the dilemma between giving one
dose to ages that are at slightly less risk or giving two doses
to those that are most vulnerable. Using England once more
as an example, supposing we had 5.5 million doses of vaccine,
these could either be used to give all those aged 80 and above
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Figure 2. Optimization of dosing strategy with respect to the number of vaccine doses and the relative efficacy of the first dose compared to the second dose.
Panels correspond to outputs for two different estimates of vaccination priority group population size and relative risk of mortality (see table 1 for further details).
(a) Age-only estimate. (b) Priority Group estimate, which included specific groups for care homes and those with underlying health conditions. In all panels, and
given a metric of maximizing deaths averted, dark shaded regions correspond to parameter sets where it was determined optimal to prioritize first doses, with light
shaded regions corresponding to parameter sets where two dose vaccination was optimal. The maximal number of doses considered corresponds to being able to









































some of those in the 70–74 years age group, one dose. To quali-
tatively assess this situation, we examined optimization
outcomes based on the two estimates for vaccination priority
group population size and relative risk of mortality (table 1).
For the age-only estimate of relative risk, the separation
between prioritizing first dose or second dose (figure 2a)
was relatively smooth. For low numbers of available doses
(less than 2 million) and greater than 50% relative efficacy,
the optimal policy is to prioritize one dose. For larger stock-
piles of vaccine, the relative efficacy needs to be higher to
prioritize giving one dose to as many people as possible.
Within the plausible range of relative efficacy values (75%–
90%), we found a steady switch to prioritizing the second
dose as the amount of available vaccine increases from
4 million to 18 million doses.
For the Priority Group estimate (figure 2b), we observed a
broadly similar pattern; however, the very high relative risk
associated with care home residents and workers (priority
group 1) means that, for a low number of doses and a low
relative efficacy, it can be optimal to prioritize giving two
doses to the care home group. With this estimated set of rela-
tive risks, there was also an even stronger effect (compared to
the age-only estimate) of high relative first dose efficacy, lead-
ing to a wider parameter space where the first dose was
prioritized.3.2. Heterogeneous strategy
We next considered strategies where a given proportion of
the available vaccine is used for first doses and the remainder
for second doses. We performed this assessment under an
assumption of maximizing the number of deaths averted
and a vaccine uptake of 90%.
Given a relative efficacy for the first dose of below 50%,
the optimal strategy is to use half of the available vaccine
for second doses, such that everyone prioritized for vacci-
nation receives two doses (figure 3). Above this threshold
of 50% relative efficacy from the first dose, the pattern of
doses reserved for second doses approximately follows thesame pattern as the homogeneous strategy (cyan and pink
lines in figure 3 are the same as in figure 2). We found a smal-
ler region of parameter space where the optimal strategy is to
only give one dose (dark blue shading), and only for a low
number of doses or very high levels of relative efficacy of
the first dose. The distinct banding observed is due to the
switch between different priority groups as the amount of
available vaccine increases. For the Priority Group estimate,
as with the homogeneous strategy, a distinct structure was
visible in the results: a two dose strategy (focused on care
homes) was optimal at around 2 million doses and for a rela-
tive first-dose efficacy of up to 70% (figure 3b).
For a given ratio of first and second doses, the associated
distribution of vaccine between the priority groups can again
be calculated due to the monotonicity of the relative risk. We
show the optimal distribution for a distinct set of relative effi-
cacies from the first dose (VER ¼ 70%, 80%, 90%) and for a
specified number of doses (4, 8, 12, 16, 20 and 24 million)
(figure 4). We show as stacked bars the number of first
(left) and second (right) doses given to each priority group
for both the simple age-structured estimates of risk and for
the full Priority Group estimates.
At 70% relative efficacy, there was a strong tendency to
offer second doses shortly after the first. Thus at 4 million
doses, the optimal strategy was to begin offering second
doses to either the oldest age group or priority group 1. For
higher levels of vaccine availability (e.g. 24 million doses),
although the distribution of second doses lags behind the
first, we consistently predict at least 50% of the groups receiv-
ing two doses of vaccine is optimal.
When relative efficacy is higher (80% or 90%) there is
more of a delay before it becomes optimal to begin second
vaccinations. At 4 million doses, the optimal strategy
became focused on delivering single doses only; with
second doses being introduced more gradually. At the most
extreme parameters investigated (90% relative vaccine effi-
cacy and full priority group estimates), even at 20 million
doses, the only group to have received their second dose
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(b)(a)
Figure 3. Optimal distribution of a given number of vaccine doses between first and second dose. Regions of parameter space in which most doses should be
prioritized towards first dose are coloured in dark blue, with gradation to yellow for an increasing proportion of doses being used as second doses. The solid lines
show the boundary between the parameter regions associated with homogeneous strategies shown in figure 2. (a) Age-only estimate; (b) Priority Group estimate.
Relative efficacies of 70%, 80% and 90% are highlighted (horizontal lines) for comparison with later plots. Vertical dashed lines show the number of vaccine doses









































Although we generated these figures by simply consider-
ing the optimal use of a fixed pool of available vaccine—with
no reference to how lower amounts of vaccine have been
used—it is still possible to read the graphs as a chronological
sequence, due to the monotonicity of the relative risk. As
such, for any given relative efficacy, the first V doses of vac-
cine are always distributed in the same manner (figure 5).
An alternative way to view the same information is to con-
sider at what point in the delivery programme it becomes
optimal to give first and second doses to each of the priority
groups. For the relative risk of mortality estimated for the full
priority groups, this visualization clarifies that at high relative
efficacy from the first dose of vaccine (90%) the optimal dis-
tribution of vaccine is substantially weighted towards early
prioritization of first doses with a substantial delay until
the second dose is offered. For completion of the first four pri-
ority groups (everyone over 70, healthcare workers, care
home staff and residents and those that are clinically extre-
mely vulnerable), we estimate that the optimal delay
between finishing the first doses and finishing the second
doses is: 12.83 million doses (for a relative efficacy of 70%),
19.58 million doses (for a relative efficacy of 80%) and 24.01
million doses (for a relative efficacy of 90%)—which is
between 6 and 12 weeks if delivery is maintained at 2 million
doses a week.4. Discussion
We have developed a simple algorithmic method that can
optimize the distribution of a fixed number of vaccine
doses, allowing us to maximize averted deaths. The JCVI
Phase 1 priority groups have been defined such that early
groups have a higher risk of mortality than lower ones
[20,25]. Hence, there is a natural ordering in which we
would wish to vaccinate priority group 1 before moving to
priority group 2. The more challenging question that we
address here is whether it is better to give high-risk groups
their second dose of vaccine before giving lower-risk groups
(in the priority order) their first dose. In the context of UK vac-
cination policy, the key question was around the delay betweenthe first and second dose, with a longer delay allowing more
individuals to be given some level of protection in the short
term. For the Oxford/AstraZeneca vaccine, there is also com-
pelling evidence that a delay of 12 weeks or more provides
greater second dose vaccine efficacy [5], strengthening the
case for an early prioritization of first doses; this has since
been enhanced by studies of the Pfizer vaccine suggesting a
longer delay may again offer better protection [17].
In countries where the total supply of vaccine is more lim-
ited, similar calculations could inform whether a strategy that
attempted to maximize coverage by only giving a single dose
would be of benefit—although, in this scenario, far more
information would be required on the long-term protection
offered by a single dose.
The key parameter in our model is the relative efficacy
provided by the first dose of vaccine compared to the level
of protection offered by two doses. Here, we have focused
on COVID-19 mortality using the relative risk of infection fol-
lowed by death for each of the nine JCVI priority groups, and
hence we are most interested in efficacy against death. Unfor-
tunately, efficacy against death is extremely difficult to
measure from Phase 3 trials (no-one taking part in the
Pfizer/BioNTech trials, in either the control or vaccine arm,
died with COVID-19 [1], with one COVID-19-related death
in one participant in the control group of Oxford/AstraZe-
neca trials [5]), and so we need to rely on data from the
large-scale national programmes. Early data from the UK
on those over 80 years of age (and therefore among the first
to receive the vaccine) suggested that a first dose of the
Pfizer/BioNTech vaccine generates a vaccine efficacy against
symptomatic infection of 70% (95% CI 59–78%) after four
weeks and an additional 51% (95% CI 37–62%) lower risk
of death if infected, giving a combined efficacy against
death of 85% [7]. This is therefore a lower-bound on our
required relative efficacy. These early estimates have since
been superseded with estimates available for both Pfizer/
BioNTech and Oxford/AstraZeneca vaccines after one and
two doses for the Alpha variant [24]; however, even in this
well-studied example there remains considerable uncertainty
in the relative efficacy of the first dose. For other variants of
concern the uncertainty in vaccine efficacy is even greater.
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Figure 4. Optimal deployment of vaccine for the two different priority group estimates and a selection of vaccine efficacies. We considered a relative efficacy of first










































We predict that, for relatively high protection from the
first dose (compared to the efficacy derived from two
doses), a substantial number of first doses should be adminis-
tered before attention switches to giving second doses
(figure 5). We expect these simple trade-offs to occur at any
point in the vaccination programme where logistical con-
strains (vaccine supply or number of trained vaccinaters)
limits uptake. As such, under these circumstances, early vac-
cine roll-out ought to be targeted towards giving as many
people one dose as possible, until the switch-point is reached.
Our results agree with findings from earlier modelling work
(applied in a non-UK context) that found, when a single doseretains the majority of the effectiveness against disease,
immunizing as many individuals as possible with a single-
dose regimen may achieve a greater reduction in disease
from COVID-19 than a two-dose regimen in a smaller
population [14–16].
While this modelling provides important generic insights
into the benefits of first and second doses, there are a number
of elements that are absent from this simple analysis. Most
notably, the vaccination programme is a dynamic process in
which different amounts of vaccine are available at different
points in time; therefore, while it is possible to read figure 5
as a chronology, it does not take into account the necessary
0
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Figure 5. Dose allocation schedule, dependent upon relative first dose efficacy. (a) Age only estimate of relative risk. (b) Priority Group estimate of relative risk. At
any point in the delivery schedule each pane shows the optimal groups that should be prioritized for vaccination. We show a smaller range of total doses for (a)









































biological restrictions on the appropriate separation between
doses. Our model computes the protection derived from a
specified amount of vaccine doses being instantaneouslyadministered among the population. This lack of a dynamic
perspective means that we cannot address questions that









































very long delays between doses may have implications for
both short- and long-term immunity; similarly, the model
cannot directly capture the delay between vaccination and
the development of immunity. Subsequent modelling studies
have since demonstrated the importance of quantifying the
characteristics and durability of vaccine-induced protection
after the first vaccine dose in order to determine the optimal
time interval between the two vaccine doses [26]. In addition,
our model also assumes that priority groups are completed in
order of greatest risk—whereas in practice, and for a number
of practical reasons, the delivery schedule is blurred, often
vaccinating groups that are most easy to reach. We expect a
schedule that mixes priority groups to lessen the advantage
of prioritizing the delivery of first doses compared to
re-vaccinating with second doses.
Our determination of dose allocation was based on avert-
ing deaths, with no regard for hospital admissions (and
therefore pressure on the health services), the implications
of long-COVID nor any form of life-years lost or quality-
adjusted life year assessment. The prioritization of first
doses compared to second doses, for a given relative efficacy,
may differ under an alternative metric or collection of
measures (as found in the study by Matrajt et al. [16], who
determined that the optimal allocation strategy with one
and two doses of vaccine was different when minimizing
one of five distinct metrics of disease and healthcare
burden under various degrees of viral transmission) and is
a topic for follow-up work. For an objective of minimizing
COVID-19 morbidity, a similar pattern of prioritization is
expected; measures of COVID-19 morbidity are consistently
higher in the elderly and vulnerable risk groups such that
these groups should be prioritized to receive their first dose
of vaccine as early as possible. However, many measures of
morbidity risk (such as hospital admissions) are not as
skewed towards older age groups as the mortality risk we
have used throughout this document, although they are still
highly age-dependent. A similar change to age-dependent
factors would occur if we considered the objective of mini-
mizing life-years lost, as mortality in older age groups
results in fewer life-years lost than mortality in younger age
groups, although analysis suggests that life-years lost to
COVID-19 is still an increasing function of age. For these
less skewed measures, there is less incentive to rapidly give
older individuals a second dose as the relative risk in older
individuals compared to younger individuals is not as
high. By this reasoning, we expect an objective of minimizing
life-years lost or COVID-19 morbidity to increase the prioriti-
zation of first doses over second doses, with second doses in
the older individuals not generating the greatest benefit until
a larger proportion of the population have been given first
doses.
In terms of the demography and empirical data on mor-
tality risk due to COVID-19, our analysis has been carriedout using data corresponding to the population of England.
Thus, these findings will not necessarily directly translate to
other settings, in particular where the population structure
and mortality rates are vastly different. Finally, our static
modelling framework does not account for the transmission
dynamics of infection; the fact that individuals have been
immunized does not change the risk to the remaining popu-
lation and hence we do not capture the structured reduction
in risk that can occur, although general declines (or increases)
in risk that apply equally to the entire population do not
affect our results. As such, our approach does not address
questions such as herd immunity nor how vaccination will
impact the long-term trajectory of the outbreak [27]. Instead,
the methods are tailored towards the early stages of a vacci-
nation programme where the aim is to reduce mortality as
rapidly as possible.
In summary, given the strong evidence that a single dose
is highly effective, our model results would indicate that
early prioritization of one dose (compared to re-vaccinating
with a second doses) averts the greater number of deaths.
The precise timing of first and second doses is contingent
on the speed of the delivery programme, with more rapid
delivery favouring early deployment of second doses. The
policy adopted in the UK was dependent upon a number
of practical considerations—not least the greater second
dose efficacy of the Oxford/AstraZeneca vaccine after a 12-
week delay [5], and the need for a simple, consistent message
across all priority groups and vaccines. However, this work
clearly shows that, given particular combinations of demo-
graphic and vaccine attributes, a strategy of prioritizing first
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